KeyNeurotek Pharmaceuticals
Pioneering the next generation of small molecule therapies for neuronal and autoimmune conditions.
Pioneering the next generation of small molecule therapies for neuronal and autoimmune conditions.
KeyNeurotek Pharmaceuticals is a biopharmaceutical company established in 2000. The company is dedicated to pioneering the next generation of small molecule therapies for neuronal and autoimmune conditions. With a focus on innovative small molecule drugs, KeyNeurotek aims to address the treatment of neuronal and autoimmune diseases. In its most recent funding round, Series C investment of €8.20M was secured on 07 April 2009. The investors participating in this round included KfW, Deutsche Venture Capital, and IBG Beteiligungsgesellschaft. KeyNeurotek operates within the biotechnology and health care industries, positioning itself at the forefront of developing solutions for complex medical challenges.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | €8.20M | 3 |
|
07 Apr 2009 |
No recent news or press coverage available for KeyNeurotek Pharmaceuticals.
We care about your data, and we'd love to use cookies make your experience better.